KENNEWICK, Wash. (PRWEB)
February 28, 2022
Researchers at Ideal Option, a national leader in evidence-based treatment for addiction to fentanyl, methamphetamine, alcohol and other substances, recently presented the largest case series to date exploring long-term buprenorphine/naloxone treatment for kratom use disorder (KUD).
Unregulated and commonly sold in gas stations and online as an anti-depressant, energy booster and pain reliever, kratom is a legal herbal supplement grown in Southeast Asia. Reports of kratom use and exposure have increased throughout the United States. Users have also taken kratom to reduce symptoms of opioid withdrawal. However, when taken in high doses, kratom can produce opioid-like effects, allowing the user to experience euphoria as well as a sedative effect.
According to the FDA, “kratom, which affects the same opioid brain receptors as morphine, appears to have properties that expose users to the risks of addiction, abuse, and dependence.” Like opioids, those who use kratom regularly can become dependent and/or experience withdrawals. In a recent case series, Ideal Option explores long-term buprenorphine treatment for KUD to reduce withdrawals and cravings similar to treating opioid use disorder (OUD).
“At Ideal Option, we use buprenorphine to treat addiction to opioids like heroin and fentanyl. With the increasing recreational use of kratom, it was necessary to study its ability to treat addiction to the herbal supplement with opioid-like effects,” said Brian Dawson, chief medical officer at Ideal Option. “After 12 weeks of treatment with buprenorphine/naloxone, 82% of participants had negative test results for mitragynine (kratom), suggesting an advantageous clinical response in patients with KUD who are treated with buprenorphine.”
In the case series, treatment plans were tailored to each individual patient to determine the appropriate buprenorphine dose. To read the full article published in the Substance Abuse journal, click here: https://bit.ly/3GB6f5z.
Ideal Option has helped nearly 50,000 patients through a network of over 70 outpatient clinics across 10 states: Alaska, Arkansas, Idaho, Maryland, Minnesota, Montana, New Mexico, North Dakota, Oregon and Washington.
With no waitlists and most forms of insurance accepted, including Medicare and Medicaid, patients can typically get started on treatment for heroin, fentanyl, kratom or other substances within 1-3 business days.
Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.
About Ideal Option
Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped nearly 50,000 patients through a network of over 70 office-based medication-assisted treatment (MAT) clinics across 10 states. With a mission to serve under-served communities, Ideal Option accepts all forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.
Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.
In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.
Share article on social media or email: